CLL/SLL

ICML 2019 | What are the latest advances in the treatment of CLL?

L: English
Watch German version

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Michael Hallek from University Hospital of Cologne, Cologne, DE, about the latest advances in the treatment of chronic lymphocytic leukemia (CLL).

Michael Hallek describes that latest therapy options emerging from recent research, focusing on monotherapies with ibrutinib being potent first-line therapies, along with the strong move towards chemotherapy-free combinations.

He described these novel agents as venetoclax, ibrutinib, and obinutuzumab, and said that they need to be further investigated as to whether all three are needed, or if a particular pair or combination works better.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF